Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alkermes (ALKS)
NASDAQ:ALKS
Alkermes (ALKS) Stock Price & Analysis
450 Followers
ALKS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.46 - $32.88
Previous Close$24.26
Volume199.95K
Average Volume (3M)2.07M
Market Cap
$4.11B
Enterprise Value$3.70B
Total Cash (Recent Filing)$773.49M
Total Debt (Recent Filing)$372.19M
Price to Earnings (P/E)9.6
Beta0.30
Next Earnings
Jul 24, 2024EPS Estimate
$0.67Last Dividend Ex-Date
Nov 16, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)2.54
Shares Outstanding169,221,311
10 Day Avg. Volume1,649,484
30 Day Avg. Volume2,070,843
Standard Deviation0.11
R-Squared0.08
Alpha-0.00318
Financial Highlights & Ratios
Price to Book (P/B)3.65
Price to Sales (P/S)2.47
Price to Cash Flow (P/CF)9.50
P/FCF Ratio10.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.23
Enterprise Value/Gross Profit2.63
Enterprise Value/Ebitda7.13
Forecast
1Y Price Target
$33.64Price Target Upside38.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Alkermes News
Bulls Say, Bears Say
Bulls Say
Financial GuidanceAlkermes reiterated 2024 guidance, reflecting confidence in achieving its financial targets for the year.
Pipeline DevelopmentKey pipeline agent ALKS 2680 has strong potential in narcolepsy type 1, with recent phase 1b data supporting a path ahead in narcolepsy type 2 as well.
Product DemandVivitrol demand continues to be driven by the alcohol dependence indication and the company continues to focus on new starts on this indication.
Bears Say
CompetitionWith the entrance of Harmony Biosciences into the orexin market, the competition has become even more crowded.
Financial Performance1Q24 results were softer-than-expected on the top and bottom line, with revenues and non-GAAP EPS missing consensus estimates.
Product PerformanceAll three core products, including Vivitrol, Aristada, and Lybalvi, experienced inventory destocking which likely impacted quarterly performance.
---
Ownership Overview
6.56% Insiders
34.62% Mutual Funds
37.12% Other Institutional Investors
21.70% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALKS FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was $20.46 and its highest was $32.88 in the past 12 months.
What is Alkermes’s market cap?
Currently, no data Available
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is Jul 24, 2024 which is in 75 days.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on May 01, 2024. The company reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.583 by -$0.153.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes pays a Notavailable dividend of $1.64 which represents an annual dividend yield of N/A. See more information on Alkermes dividends here
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is $0.67.
How many shares outstanding does Alkermes have?
Alkermes has 169,221,310 shares outstanding.
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of $0.43 in its last earnings report, missing expectations of $0.583. Following the earnings report the stock price went down -2.16%.
Which hedge fund is a major shareholder of Alkermes?
Among the largest hedge funds holding Alkermes’s share is PRIMECAP Management Co. It holds Alkermes’s shares valued at 99M.
---
Alkermes Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.64 (38.66% Upside)
$33.64 (38.66% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 346.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.59%
12-Months-Change
Fundamentals
Return on Equity
42.85%
Trailing 12-Months
Asset Growth
10.46%
Trailing 12-Months
Company Description
Alkermes
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
---
ALKS Company Deck
---
ALKS Earnings Call
Q1 2024
0:00 / 0:00
---
ALKS Revenue Breakdown
55.31% Product sales, net
44.69% Manufacturing and royalty revenues
<0.01% Research and development revenue
0.00% License revenue
---
ALKS Stock 12 Month Forecast
Average Price Target
$33.64
▲(38.66% Upside)
Technical Analysis
Best Analysts Covering ALKS
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+0.35%
assigned a buy rating last month
Copying Akash Tewari's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +0.35% per trade.
---